دورية أكاديمية
OncoLoop: A Network-Based Precision Cancer Medicine Framework.
| العنوان: | OncoLoop: A Network-Based Precision Cancer Medicine Framework. |
|---|---|
| المؤلفون: | Vasciaveo A; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Arriaga JM; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., de Almeida FN; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Zou M; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Douglass EF; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Picech F; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Shibata M; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Genetics and Development, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Urology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Rodriguez-Calero A; Department for Biomedical Research, University of Bern, Bern, Switzerland.; Institute of Pathology, University of Bern and Inselspital, Bern, Switzerland., de Brot S; COMPATH, Institute of Animal Pathology, University of Bern, Bern, Switzerland., Mitrofanova A; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Chua CW; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Genetics and Development, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Urology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Karan C; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; J.P. Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, New York., Realubit R; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; J.P. Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, New York., Pampou S; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; J.P. Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, New York., Kim JY; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Afari SN; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Mukhammadov T; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Zanella L; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Corey E; Department of Urology, University of Washington, Seattle, Washington., Alvarez MJ; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; DarwinHealth Inc., New York, New York., Rubin MA; Department for Biomedical Research, University of Bern, Bern, Switzerland.; Bern Center for Precision Medicine (BCPM), Bern, Switzerland., Shen MM; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Genetics and Development, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Urology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York., Califano A; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; J.P. Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, New York.; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.; Department of Biochemistry and Molecular Biophysics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York., Abate-Shen C; Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Department of Urology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.; Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York. |
| المصدر: | Cancer discovery [Cancer Discov] 2023 Feb 06; Vol. 13 (2), pp. 386-409. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research |
| مواضيع طبية MeSH: | Prostatic Neoplasms, Castration-Resistant*/pathology, Male ; Mice ; Animals ; Humans ; Precision Medicine ; Androgen Receptor Antagonists ; Transcriptome ; Gene Expression Profiling ; Nitriles ; Receptors, Androgen/genetics |
| مستخلص: | Prioritizing treatments for individual patients with cancer remains challenging, and performing coclinical studies using patient-derived models in real time is often unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework that predicts drug sensitivity in human tumors and their preexisting high-fidelity (cognate) model(s) by leveraging drug perturbation profiles. As a proof of concept, we applied OncoLoop to prostate cancer using genetically engineered mouse models (GEMM) that recapitulate a broad spectrum of disease states, including castration-resistant, metastatic, and neuroendocrine prostate cancer. Interrogation of human prostate cancer cohorts by Master Regulator (MR) conservation analysis revealed that most patients with advanced prostate cancer were represented by at least one cognate GEMM-derived tumor (GEMM-DT). Drugs predicted to invert MR activity in patients and their cognate GEMM-DTs were successfully validated in allograft, syngeneic, and patient-derived xenograft (PDX) models of tumors and metastasis. Furthermore, OncoLoop-predicted drugs enhanced the efficacy of clinically relevant drugs, namely, the PD-1 inhibitor nivolumab and the AR inhibitor enzalutamide. Significance: OncoLoop is a transcriptomic-based experimental and computational framework that can support rapid-turnaround coclinical studies to identify and validate drugs for individual patients, which can then be readily adapted to clinical practice. This framework should be applicable in many cancer contexts for which appropriate models and drug perturbation data are available. This article is highlighted in the In This Issue feature, p. 247. (©2022 American Association for Cancer Research.) |
| References: | Cell. 2014 Sep 25;159(1):176-187. (PMID: 25201530) N Engl J Med. 2018 Feb 15;378(7):645-657. (PMID: 29412780) Nat Genet. 2016 Aug;48(8):838-47. (PMID: 27322546) Nat Commun. 2018 Dec 5;9(1):5201. (PMID: 30518758) Nat Commun. 2018 Sep 19;9(1):3815. (PMID: 30232459) Nat Genet. 2019 Oct;51(10):1427-1428. (PMID: 31548719) Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. (PMID: 31061129) Nat Commun. 2020 Nov 4;11(1):5579. (PMID: 33149111) Br J Cancer. 2013 Oct 1;109(7):1711-6. (PMID: 24008662) Nat Commun. 2017 Jul 24;8(1):105. (PMID: 28740083) Cancer Res. 2012 Sep 1;72(17):4483-93. (PMID: 22815528) Nat Cancer. 2021 Feb;2(2):233-244. (PMID: 34223192) Cancer Discov. 2017 Jul;7(7):736-749. (PMID: 28411207) Cell Rep Med. 2022 Jan 18;3(1):100492. (PMID: 35106508) J Clin Invest. 2021 Dec 15;131(24):. (PMID: 34907913) Nature. 2009 Sep 24;461(7263):495-500. (PMID: 19741607) Nat Neurosci. 2010 Jan;13(1):133-40. (PMID: 20023653) Cell Death Dis. 2013 Oct 24;4:e878. (PMID: 24157872) Nat Neurosci. 2015 Sep;18(9):1325-33. (PMID: 26214373) Nat Rev Drug Discov. 2022 Mar;21(3):181-200. (PMID: 35042991) Cell. 2021 Jan 21;184(2):334-351.e20. (PMID: 33434495) Nat Rev Cancer. 2015 Dec;15(12):701-11. (PMID: 26563462) Cancer Res. 2019 May 15;79(10):2580-2592. (PMID: 30952632) Endocr Relat Cancer. 2001 Sep;8(3):249-58. (PMID: 11566616) Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):. (PMID: 29661807) Nat Med. 2019 May;25(5):751-758. (PMID: 31011205) Cancer Cell. 2014 May 12;25(5):638-651. (PMID: 24823640) Nat Commun. 2018 Jun 19;9(1):2404. (PMID: 29921838) CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946) Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):E3506-15. (PMID: 23918374) Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. (PMID: 22508028) Science. 2017 Jan 6;355(6320):84-88. (PMID: 28059768) Nat Genet. 2013 Jun;45(6):580-5. (PMID: 23715323) Annu Rev Pathol. 2020 Jan 24;15:211-234. (PMID: 31550983) Clin Cancer Res. 2014 Mar 15;20(6):1542-54. (PMID: 24486586) Nat Commun. 2021 Jan 4;12(1):22. (PMID: 33397959) Cancer Chemother Pharmacol. 2013 Sep;72(3):537-44. (PMID: 23820963) Nat Genet. 2005 Apr;37(4):382-90. (PMID: 15778709) Genes Dev. 2007 Feb 15;21(4):379-84. (PMID: 17299132) Cancer Cell. 2015 Feb 9;27(2):223-39. (PMID: 25670080) Cell. 2004 Dec 17;119(6):847-60. (PMID: 15607980) Nat Med. 2016 Mar;22(3):298-305. (PMID: 26855148) Nat Genet. 2018 May;50(5):645-651. (PMID: 29610475) J Clin Oncol. 2005 Nov 10;23(32):8253-61. (PMID: 16278481) Genes Dev. 2010 Sep 15;24(18):1967-2000. (PMID: 20844012) Cancer Cell. 2003 Sep;4(3):223-38. (PMID: 14522256) Sci Transl Med. 2019 Apr 17;11(488):. (PMID: 30996079) Cancer Immunol Res. 2021 May;9(5):529-541. (PMID: 33637604) Genesis. 2002 Feb;32(2):148-9. (PMID: 11857804) Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944) Clin Cancer Res. 2013 Sep 1;19(17):4889-99. (PMID: 23780888) Nat Genet. 2018 Jul;50(7):979-989. (PMID: 29915428) J Pathol. 2021 Aug;254(5):543-555. (PMID: 33934365) Nat Commun. 2021 Mar 30;12(1):1979. (PMID: 33785741) Cell. 2021 May 27;184(11):2988-3005.e16. (PMID: 34019793) Cell. 2013 Dec 5;155(6):1309-22. (PMID: 24315100) Nat Cell Biol. 2014 Oct;16(10):951-61, 1-4. (PMID: 25241035) Genes Dev. 2001 Dec 15;15(24):3243-8. (PMID: 11751630) Nat Cancer. 2020 Nov;1(11):1082-1096. (PMID: 34085047) Nat Med. 2013 Aug;19(8):1023-9. (PMID: 23817021) Nat Commun. 2021 Feb 18;12(1):1117. (PMID: 33602919) EMBO Mol Med. 2017 Feb;9(2):137-153. (PMID: 28028012) Front Oncol. 2018 Feb 19;8:19. (PMID: 29515970) Cell Metab. 2018 Apr 3;27(4):714-739. (PMID: 29617640) Nat Med. 2017 Jun 6;23(6):1-10. (PMID: 28586335) Cancer Res. 2012 Sep 15;72(18):4765-76. (PMID: 22836754) Genome Biol. 2015 Feb 02;16:68. (PMID: 25886852) EMBO J. 2019 Aug 1;38(15):e101654. (PMID: 31282586) Science. 2009 May 8;324(5928):787-90. (PMID: 19359544) Prostate. 2017 May;77(6):654-671. (PMID: 28156002) |
| معلومات مُعتمدة: | R01 CA238005 United States CA NCI NIH HHS; U01 CA261822 United States CA NCI NIH HHS; S10 OD012351 United States OD NIH HHS; P01 CA265768 United States CA NCI NIH HHS; P30 CA013696 United States CA NCI NIH HHS; U01 CA217858 United States CA NCI NIH HHS; S10 OD021764 United States OD NIH HHS; UL1 TR001873 United States TR NCATS NIH HHS; P01 CA163227 United States CA NCI NIH HHS; R00 CA194287 United States CA NCI NIH HHS; U01 CA272610 United States CA NCI NIH HHS; U54 CA209997 United States CA NCI NIH HHS; P50 CA097186 United States CA NCI NIH HHS; R01 CA173481 United States CA NCI NIH HHS; P01 CA221757 United States CA NCI NIH HHS; R01 CA183929 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Androgen Receptor Antagonists) 0 (Nitriles) 0 (Receptors, Androgen) |
| تواريخ الأحداث: | Date Created: 20221114 Date Completed: 20230207 Latest Revision: 20230807 |
| رمز التحديث: | 20230807 |
| مُعرف محوري في PubMed: | PMC9905319 |
| DOI: | 10.1158/2159-8290.CD-22-0342 |
| PMID: | 36374194 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2159-8290 |
|---|---|
| DOI: | 10.1158/2159-8290.CD-22-0342 |